Skip to main content
    G

    Guardian Pharmacy Services, Inc. (GRDN)

    Official site

    HEALTHCARE • MEDICAL CARE FACILITIES • NYSE

    $49.42
    -0.09 (-0.19%)

    Market Cap: $3.14B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Guardian Pharmacy Services, Inc. (GRDN) P/E Ratio & Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Guardian Pharmacy Services (GRDN) trades at 41.2x trailing earnings and 2.1x sales. Its forward P/E is 33.2x. The median P/E across 11 similar companies is 25.3x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 24.1% higher over the next year. Its free cash flow yield is 2.9%.

    MultipleValue
    P/E (trailing)41.2x
    Forward P/E33.2x
    Price to sales2.1x
    Price to book11.7x
    EV/EBITDA23.3x
    Price to FCF34.3x
    EV/FCF33.0x
    PEGN/A
    FCF yield2.9%

    As of Nov 17, 2026

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About GRDN

    What is GRDN's forward P/E ratio?

    Guardian Pharmacy Services has a forward P/E ratio of 33.2x.

    Is GRDN stock overvalued?

    GNG's valuation label for GRDN is Fairly valued. Its P/E of 41.2x compares with a median of 25.3x across 11 similar companies.

    What is GRDN's price to sales ratio?

    Guardian Pharmacy Services has a price to sales ratio of 2.1x.